Compare · DFTX vs ISPR
DFTX vs ISPR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Ispire Technology Inc. (ISPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and ISPR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 26.3x ISPR ($97.6M).
- Over the past year, DFTX is up 203.4% and ISPR is down 38.5% - DFTX leads by 241.9 points.
- DFTX has hit the wire 3 times in the past 4 weeks while ISPR has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 1 for ISPR).
PerformanceDFTX+203.41%ISPR-38.49%
2025-06-09+0.00%2026-06-05
- Company
- Definium Therapeutics Inc.
- Ispire Technology Inc.
- Price
- $23.56-4.23%
- $1.71+3.64%
- Market cap
- $2.57B
- $97.6M
- 1M return
- +0.68%
- +1.18%
- 1Y return
- +203.41%
- -38.49%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 3
- 0
- Recent ratings
- 4
- 1
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest ISPR
- SEC Form DEFA14A filed by Ispire Technology Inc.
- SEC Form DEF 14A filed by Ispire Technology Inc.
- SEC Form 10-Q filed by Ispire Technology Inc.
- Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026
- Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call
- IKETech Wins "Privacy-Centric Age Assurance Solution of the Year," Recognized for Innovation at Global Industry Awards
- IKE Tech Engages FDA on Next-Generation Compliance Infrastructure for ENDS
- SEC Form 4 filed by Fargis John
- SEC Form 4 filed by Cox Brent
- SEC Form 4 filed by Burch Christopher Robert